| 李迎春,金爱山,陈 诗.130例结直肠癌术后辅助化疗联合CIK治疗的临床疗效评价[J].肿瘤学杂志,2015,21(10):843-847. |
| 130例结直肠癌术后辅助化疗联合CIK治疗的临床疗效评价 |
| Efficacy of Adjuvant Chemotherapy Combined with CIK Cell Immunotherapy in 130 Patients with Postoperative Colorectal Cancer |
| 投稿时间：2015-04-22 |
| DOI：10.11735/j.issn.1671-170X.2015.10.B013 |
|
 |
| 中文关键词: 结直肠肿瘤 CIK治疗 临床疗效 无病生存率 总生存率 |
| 英文关键词:colorectal neoplasms cytokine-induced killer (CIK) clinical efficacy DFS OS |
| 基金项目: |
|
| 摘要点击次数: 2316 |
| 全文下载次数: 876 |
| 中文摘要: |
| 摘 要：［目的］ 评价术后辅助化疗联合细胞因子诱导的杀伤细胞（CIK）免疫治疗在结直肠癌治疗中的作用。［方法］ 连续收集2006年3月至2009年12月接受结直肠癌根治术后行辅助化疗联合≥4次CIK治疗的65例患者为CIK治疗组，采用1∶1方法，并按照病理分期、肿瘤部位、年龄等因素选择同期结直肠癌根治术后单纯接受辅助化疗的65例患者为对照组。随访截止至2014年5月。t检验、χ2检验/Fisher精确检验比较两组临床资料。观察终点为无病生存期（DFS）和总生存期（OS）。［结果］ CIK治疗组1、2、3、4、5年无病生存率分别为82%、55%、43%、34%、30%，而对照组分别为63%、31%、27%、20%、19%（P<0.05）。CIK治疗组中位DFS明显优于对照组（27个月vs 16个月，P<0.05）。CIK治疗组1、2、3、4、5年总生存率分别为98%、94%、80%、72%、66%，而对照组分别为95%、84%、63%、53%、45%（P<0.05）。CIK治疗组中位OS明显优于对照组（74个月vs 54个月，P<0.05）。CIK治疗是患者预后的影响因素（P<0.05）。亚组分析显示，≥9次治疗的患者OS优于＜9次的患者（P<0.05）。［结论］ 结直肠癌根治术后联合CIK治疗能够显著改善预后，且增加CIK治疗次数可以使患者更大程度获益。 |
| 英文摘要: |
| Abstract：［Purpose］ To evaluate the clinical efficacy of cytokine-induced killer cells (CIK) combined with adjuvant chemotherapy in the treatment of postoperative patients with colorectal cancer (CRC). ［Methods］ Baseline characteristics and outcomes of 130 CRC patients treated by adjuvant chemotherapy after radical resection were collected from March 2006 to December 2009. A total of 65 patients received ≥4 cycles of autologous CIK cell treatment (CIK group)，and 65 received adjuvant chemotherapy only (control group) were chosen in respect of pathological stage，location of the tumor，age and so on. The patients were followed up until May 2014. Differences in demographic，clinical characteristics and therapeutic information of patients between the two groups were evaluated using t test，χ2 test and the Fisher exact test as appropriate. Disease-free survival(DFS) and overall survival(OS) were evaluated. ［Results］ The 1，2，3，4，5-year DFS rates in CIK group were markedly higher than those in control group (82%，55%，43%，34%，30% vs 63%，31%，27%，20%，19%，P<0.05). The median DFS durations in CIK group were significantly better than those in control group (27 months vs 16 months，P<0.05). The 1，2，3，4，5-year OS rates in CIK group were markedly higher than those in control group(98%，94%，80%，72%，66% vs 95%，84%，63%，53%，45%，P<0.05). The median OS durations in CIK group were significantly better than those in control group(74 months vs 54 months，P<0.05). CIK cell immunotherapy was significantly related with the OS duration(P<0.05). In subgroup analysis，patients who received≥9 cycles of CIK cell transfusion exhibited significantly better survival than the ＜9 cycle group(P<0.05). ［Conclusion］ Adjuvant chemotherapy combined with CIK cell immunotherapy can improve the prognosis of CRC， and increasing the frequency of CIK cell treatment seems to benefit patients more. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |